These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33411375)

  • 1. Impact of age on adherence and efficacy of peanut oral-immunotherapy using a standardized protocol.
    Zhu R; Robertson K; Protudjer JLP; Macikunas A; Kim R; Jeimy S; Kim H
    Pediatr Allergy Immunol; 2021 May; 32(4):783-786. PubMed ID: 33411375
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse reactions during peanut oral immunotherapy home dosing.
    Varshney P; Steele PH; Vickery BP; Bird JA; Thyagarajan A; Scurlock AM; Perry TT; Jones SM; Burks AW
    J Allergy Clin Immunol; 2009 Dec; 124(6):1351-2. PubMed ID: 19913285
    [No Abstract]   [Full Text] [Related]  

  • 3. Considerations for the Initiation and Implementation of Early Peanut Oral Immunotherapy.
    Leeds S; Kim EH
    J Allergy Clin Immunol Pract; 2023 Oct; 11(10):3275-3276.e9. PubMed ID: 37805226
    [No Abstract]   [Full Text] [Related]  

  • 4. Low dose immunotherapy in very young children to treat peanut allergy.
    Vickery BP
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1251-1253. PubMed ID: 27599211
    [No Abstract]   [Full Text] [Related]  

  • 5. Peanut oral immunotherapy: Reconsidering a one-size-fits-all approach.
    Nair LG; Capucilli P
    Ann Allergy Asthma Immunol; 2022 Sep; 129(3):265-266. PubMed ID: 35817676
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia.
    Patrawala S; Ramsey A; Capucilli P; Tuong LA; Vadamalai K; Mustafa SS
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1120-1122.e1. PubMed ID: 34979334
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and effectiveness of peanut oral immunotherapy in children under 12 months.
    Johnson SR; McNamara K; Bjelac J; Kerns LA; Subramanian A; Hoyt AEW; Whitsel R; Hong SJ
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3544-3546.e1. PubMed ID: 37453570
    [No Abstract]   [Full Text] [Related]  

  • 8. Evening ingestion as a potential reaction cofactor during peanut oral immunotherapy in children.
    Morris E; Protudjer JLP; Jeimy S; Edgerley S; Rondilla N; Robertson K; Zhu R; Kim H
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1964-1966.e2. PubMed ID: 36889670
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up of children who achieved sustained unresponsiveness after peanut oral immunotherapy.
    Lee ASE; Baker MG; Cox AL; Oriel RC; Tsuang A; Sicherer SH; Kattan JD
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):255-256. PubMed ID: 37852440
    [No Abstract]   [Full Text] [Related]  

  • 10. Peanut oral immunotherapy protects patients from accidental allergic reactions to peanut.
    Trendelenburg V; Blumchen K; Bellach J; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Röder M; Niggemann B; Beyer K
    J Allergy Clin Immunol Pract; 2020; 8(7):2437-2441.e3. PubMed ID: 32304836
    [No Abstract]   [Full Text] [Related]  

  • 11. Would oral desensitization for peanut allergy be safer than avoidance?
    Brown HM
    Ann Allergy Asthma Immunol; 2007 Feb; 98(2):203. PubMed ID: 17304895
    [No Abstract]   [Full Text] [Related]  

  • 12. Weighing peanut candies used for oral immunotherapy mitigates variable peanut protein dose.
    Mack DP; Foster GA; Mack JD; Mack LC; Hanna MA
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):521-523.e1. PubMed ID: 32818698
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence for sustained desensitization after sublingual peanut immunotherapy.
    Bohle B
    J Allergy Clin Immunol; 2023 Jun; 151(6):1477-1478. PubMed ID: 37086923
    [No Abstract]   [Full Text] [Related]  

  • 14. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization.
    Bird JA; Feldman M; Arneson A; Dougherty I; Brown LS; Burk CM; Kulis M; Burks W; Gill M
    J Allergy Clin Immunol Pract; 2015; 3(3):433-5.e1-3. PubMed ID: 25609341
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized controlled trial of slow peanut oral immunotherapy in young children: SmaChO study protocol.
    Uhl C; Sverremark-Ekström E; Borres M; Ebisawa M; Melén E; Mäkelä MJ; Konradsen JR; Vickery BP; Asarnoj A; Nilsson C
    Clin Exp Allergy; 2023 May; 53(5):594-597. PubMed ID: 37098849
    [No Abstract]   [Full Text] [Related]  

  • 16. Current opinion and review on peanut oral immunotherapy.
    Deol S; Bird JA
    Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy.
    Brown-Whitehorn TF; de Blay F; Spergel JM; Green TD; Peillon A; Sampson HA; Campbell DE
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):524-526. PubMed ID: 32835872
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term outcomes of peanut immunotherapy in children.
    Dantzer JA; Mudd K; Wood RA
    J Allergy Clin Immunol Pract; 2020 May; 8(5):1753-1756.e2. PubMed ID: 31927100
    [No Abstract]   [Full Text] [Related]  

  • 19. Five-year follow-up of early intervention peanut oral immunotherapy.
    Herlihy L; Kim EH; Burks AW; Barber H; Cook Q; Yang L; Hamilton D; Vickery BP
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):514-517. PubMed ID: 32707238
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA-approved peanut allergy treatment: The first wave is about to crest.
    Tilles SA; Petroni D
    Ann Allergy Asthma Immunol; 2018 Aug; 121(2):145-149. PubMed ID: 29909055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.